These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37189660)

  • 1. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors.
    Mohamed KM; Guevara-Hoyer K; García CJ; Bravo LG; Jiménez-Huete A; de la Peña AR; Valeros BM; Velázquez CC; López EC; Cabello N; Estrada V; Corbí ÁL; Fernández-Arquero M; Ocaña A; Delgado-Iribarren A; Martínez-Novillo M; Bolaños E; Anguita E; Peña A; Benavente C; Benítez Fuentes JD; Pérez Segura P; Sánchez-Ramón S
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
    Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E
    Front Immunol; 2022; 13():858399. PubMed ID: 35401575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency.
    Murray CE; O'Brien C; Alamin S; Phelan SH; Argue R; Kiersey R; Gardiner M; Naughton A; Keogh E; Holmes P; Naughton S; Scanlon A; Sloan A; McCrea P; Sui J; Dunne J; Conlon N
    Front Immunol; 2023; 14():1131604. PubMed ID: 37033955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.
    Shields AM; Tadros S; Al-Hakim A; Nell JM; Lin MMN; Chan M; Goddard S; Dempster J; Dziadzio M; Patel SY; Elkalifa S; Huissoon A; Duncan CJA; Herwadkar A; Khan S; Bethune C; Elcombe S; Thaventhiran J; Klenerman P; Lowe DM; Savic S; Burns SO; Richter AG
    Front Immunol; 2022; 13():984376. PubMed ID: 36211396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy.
    Mohamed Mohamed K; Álvarez-Hernández MP; Jiménez García C; Guevara-Hoyer K; Freites D; Martínez Prada C; Pérez-Sancristóbal I; Fernández Gutiérrez B; Mato Chaín G; Rodero M; Rodríguez de la Peña A; Mulero T; Bravo C; Toledano E; Culebras López E; Mediero Valeros B; Pérez Segura P; Sánchez-Ramón S; Candelas Rodríguez G
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.
    La Civita E; Zannella C; Brusa S; Romano P; Schettino E; Salemi F; Carrano R; Gentile L; Punziano A; Lagnese G; Spadaro G; Franci G; Galdiero M; Terracciano D; Portella G; Loffredo S
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37632002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
    Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
    J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK.
    Shields AM; Anantharachagan A; Arumugakani G; Baker K; Bahal S; Baxendale H; Bermingham W; Bhole M; Boules E; Bright P; Chopra C; Cliffe L; Cleave B; Dempster J; Devlin L; Dhalla F; Diwakar L; Drewe E; Duncan C; Dziadzio M; Elcombe S; Elkhalifa S; Gennery A; Ghanta H; Goddard S; Grigoriadou S; Hackett S; Hayman G; Herriot R; Herwadkar A; Huissoon A; Jain R; Jolles S; Johnston S; Khan S; Laffan J; Lane P; Leeman L; Lowe DM; Mahabir S; Lochlainn DJM; McDermott E; Misbah S; Moghaddas F; Morsi H; Murng S; Noorani S; O'Brien R; Patel S; Price A; Rahman T; Seneviratne S; Shrimpton A; Stroud C; Thomas M; Townsend K; Vaitla P; Verma N; Williams A; Burns SO; Savic S; Richter AG
    Clin Exp Immunol; 2022 Sep; 209(3):247-258. PubMed ID: 35641155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in
    Jalil M; Rowane M; Rajan J; Hostoffer R
    Allergy Rhinol (Providence); 2021; 12():21526567211056239. PubMed ID: 34868726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of the Spikevax® (Moderna) mRNA SARS-CoV-2 Vaccine in Patients with Primary Humoral Immunodeficiency.
    Kralickova P; Jankovicova K; Sejkorova I; Soucek O; Koprivova K; Drahosova M; Andrys C; Krejsek J
    Int Arch Allergy Immunol; 2022; 183(12):1297-1310. PubMed ID: 36202084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
    Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients.
    Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.